Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

BACKGROUND: The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A1c (HbA1c) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone vers...

Full description

Bibliographic Details
Main Authors:	Taro Kishi, Yuki Matsuda, Nakao Iwata
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3913743?pdf=render

Similar Items

Early prediction of blonanserin response in Japanese patients with schizophrenia
by: Kishi T, et al.
Published: (2014-09-01)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
by: Kishi T, et al.
Published: (2016-11-01)

Profile of blonanserin for the treatment of schizophrenia
by: Tenjin T, et al.
Published: (2013-04-01)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
by: Kishi T, et al.
Published: (2015-02-01)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
by: Taro Kishi, et al.
Published: (2015-01-01)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
by: Oya K, et al.
Published: (2015-09-01)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
by: Okuyama Y, et al.
Published: (2016-12-01)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
by: Hashimoto Kenji, et al.
Published: (2010-04-01)

Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.
by: Shinji Matsunaga, et al.
Published: (2015-01-01)

Prolactin Levels in Schizophrenic Patients Receiving Perospirone in Comparison to Risperidone
by: Takashi Togo, et al.
Published: (2003-01-01)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
by: Kishi T, et al.
Published: (2014-12-01)

Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances
by: Yoshifumi Inoue, et al.
Published: (2021-01-01)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
by: Hori H, et al.
Published: (2014-03-01)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
by: Imamura, A., et al.
Published: (2021)

Blonanserin overdose: A case report
by: Sandeep Kumar Goyal, et al.
Published: (2019-01-01)

Blonanserin suppresses impulsive action in rats
by: Naoya Nishitani, et al.
Published: (2019-11-01)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
by: Mitsukuni Murasaki, et al.
Published: (2021-09-01)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
by: Yunliang Zheng, et al.
Published: (2014-01-01)

Impact of soy milk consumption on cardiometabolic risk factors: A systematic review and meta-analysis of randomized controlled trials
by: Mohammad Hassan Sohouli, et al.
Published: (2021-08-01)

Blonanserin – A Novel Antianxiety and Antidepressant Drug? An Experimental Study
by: Ramchandra Prabhakar Limaye, et al.
Published: (2016-09-01)

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial
by: Bo, Q., et al.
Published: (2022)

The Effect of Probiotics and Synbiotics on Risk Factors Associated with Cardiometabolic Diseases in Healthy People—A Systematic Review and Meta-Analysis with Meta-Regression of Randomized Controlled Trials
by: Karolina Skonieczna-Żydecka, et al.
Published: (2020-06-01)

Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia—A Systematic Review
by: Ewa Tumiel, et al.
Published: (2019-08-01)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
by: Kishi T, et al.
Published: (2018-10-01)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
by: Kishi T, et al.
Published: (2017-05-01)

Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study
by: Lyang Huh, et al.
Published: (2019-10-01)

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses
by: Taro Kishi, et al.
Published: (2018-01-01)

Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride
by: TS DEEPAK, et al.
Published: (2015-06-01)

Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
by: Okazaki K, et al.
Published: (2016-12-01)

Perospirone, a Novel Antipsychotic Agent, Hyperpolarizes Rat Dorsal Raphe Neurons via 5-HT1A Receptor
by: Tsuguka Shiwa, et al.
Published: (2003-01-01)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
by: Kishi T, et al.
Published: (2018-10-01)

Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials
by: Iolanda Cioffi, et al.
Published: (2018-12-01)

Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range
by: Satoko Baba, et al.
Published: (2015-03-01)

Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Peyman Nowrouzi-Sohrabi, et al.
Published: (2021-03-01)

Exercise in Pregnancy and Children’s Cardiometabolic Risk Factors: a Systematic Review and Meta-Analysis
by: Laetitia Guillemette, et al.
Published: (2018-08-01)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
by: Kishi T, et al.
Published: (2019-05-01)

Effects of Fish Oil Supplementation on Cardiometabolic Risk Factors in Overweight or Obese Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials
by: Shaojing Wu, et al.
Published: (2021-04-01)

Global prevalence of cardiometabolic risk factors in the military population: a systematic review and meta-analysis
by: Fereshteh Baygi, et al.
Published: (2020-01-01)

Neck circumference and its association with cardiometabolic risk factors: a systematic review and meta-analysis
by: Asal Ataie-Jafari, et al.
Published: (2018-09-01)

Effects of Anthocyanins in Composite Meals on Cardiometabolic Outcomes—A Systematic Review of Randomized Controlled Feeding Trials
by: Jun Leong Sean Ou, et al.
Published: (2020-12-01)